<div id="readability-page-1"><div><ul><li>Zura Bio Ltd is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025</li><li></li><li>​LSEG's mean analyst estimate for Zura Bio Ltd is for a loss of 18 cents per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 6 &#34;strong buy&#34; or &#34;buy,&#34; 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Zura Bio Ltd is $13.50, about 71.6% above its last closing price of $3.84</li></ul>Previous quarterly performance (using preferred earnings measure in US dollars). ​<div><table><tbody><tr><td>QUARTER ENDING</td><td>STARMINESMARTESTIMATE®</td><td>LSEG IBES ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td><td>SURPRISE %</td></tr><tr><td>Jun. 30 2025</td><td>-0.18</td><td>-0.19</td><td>-0.17</td><td>Beat</td><td>9.7</td></tr><tr><td>Mar. 31 2025</td><td>-0.15</td><td>-0.16</td><td>-0.19</td><td>Missed</td><td>-19.8</td></tr><tr><td>Dec. 31 2024</td><td></td><td>-0.16</td><td>-0.10</td><td>Beat</td><td>35.6​</td></tr><tr><td>Sep. 30 2024</td><td>-0.12</td><td>-0.12</td><td>-0.26</td><td>Missed</td><td>-110.8</td></tr><tr><td>​​Jun. 30 2024</td><td>-0.16</td><td>-0.15</td><td>-0.17</td><td>Missed</td><td>-13.5</td></tr><tr><td>Mar. 31 2024</td><td>-0.22</td><td>-0.23</td><td>-0.02</td><td>Beat</td><td>91.4​</td></tr><tr><td>Dec. 31 2023</td><td></td><td>-0.23</td><td>-0.19</td><td>Beat</td><td>17.5</td></tr><tr><td>Sep. 30 2023</td><td>-0.25</td><td>-0.25</td><td>-0.18</td><td>Beat</td><td>27.4</td></tr></tbody></table></div>This summary was machine generated November 3 at 14:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</div></div>

ZURA

Zura Bio Ltd is expected to report a loss of 18 cents per share for the quarter ending September 30, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $13.50, representing a 71.6% increase from the last closing price of $3.84. Previous quarterly performances show mixed results, with some earnings beats and misses. The earnings estimate has remained unchanged over the last three months.

Zura Bio Ltd expected to post a loss of 18 cents a share - Earnings Preview